Introduction
The myelodysplastic syndromes (MDS) are a heterogenous group of clonal disorders characterized by dysplasia, ineffective hematopoiesis and cytopenias, with progressive evolution to acute leukemia in 25% of cases. 1 There is increasing evidence to suggest that immunological dysregulation plays an important role contributing to ineffective hematopoiesis and progressive cytopenias. There is a recognized association between autoimmune phenomenon, such as connective tissue disorders and systemic vasculitic disorders with the presence of MDS. [2] [3] [4] [5] Clinical and laboratory findings have suggested an autoimmune mediated component to the pancytopenia and bone marrow (BM) failure seen in MDS [6] [7] [8] [9] with observations of increased oligoclonal expansion of T cells and possible cytotoxic T-cellmediated suppression of Hematopoietic progenitors. [10] [11] [12] Immunosuppressive therapy has been shown to induce sustained hematological responses in a subset of patients with MDS. In particular, antithymocyte globulin (ATG), a polyclonal immunoglobulin, induces hematological responses in up to 60% of MDS patients. 7, [13] [14] [15] [16] [17] ATG is known to react with a number of cell types that include T cells and natural killer cells, as well as molecules modulating the immune response, such as integrins and certain chemokine receptors. 18 While its precise mechanism of action remains unclear, it is believed to involve the amelioration of lymphocyte-mediated suppression of the BM environment. 11 Herein, we report on the results of a retrospective multicenter study into the use of ATG in the treatment of MDS. A total of 96 patients were treated with ATG and we review the impact of pretreatment variables on the hematological response to ATG.
Materials and methods

Patient demographics
A total of 96 patients from centers in UK (n ¼ 65), Germany (n ¼ 13) and Italy (n ¼ 18) were treated with ATG (Lymphoglobuline, SangStat). All patients had an established diagnosis of MDS, with the subtype of MDS as defined by the FrenchAmerican-British (FAB) criteria. 19 Data were collected from the various centers using regular data forms, which were reviewed and complied by ZL. The cohort includes 30 patients previously reported in a UK-based pilot study on the use of ATG for patients with 'low-risk' MDS 7 with extended follow-up, as well as 66 patients treated off study as the best available treatment for their disease. Blood and BM morphology in all patients were reviewed critically, and BM hypocellularity was defined by o20% cellularity. Cytogenetics studies were performed at initial presentation, and cytogenetic results were accepted only in patients with at least 20 analyzable metaphases. Paroxysmal noctural hemoglobinuria (PNH) clones were detected by the analysis of glycophosphatidylinositol-anchored membrane proteins on granulocytes performed by flow cytometry, using monoclonal antibody specific to CD55, CD59 and CD66b. In addition, the following hematological criteria were met: hemoglobin concentration (Hb) o10 g/dl or red cell transfusion dependence of 42 U every 4 weeks for at least 2 months, or thrombocytopenia with platelets o100 Â 10 9 /l and with significant hemorrhage, or neutropenia with an absolute neutrophil count o1. 
ATG protocol
A single treatment course of lymphoglobuline (Sangstat) was administered (1.5 vials/10 kg/day for 5 days; 1 vial contains 100 mg protein). A test dose of one-tenth of a vial was given before giving the full dose. Before each daily dose of lymphoglobuline, hydrocortisone 100 mg and chlorpheniramine 10 mg was given as hypersensitivity prophylaxis. Antibiotic, antifungal and septrin (co-trimoxazole) prophylaxis was given to all patients together with oral prednisolone for the prevention of serum sickness in accordance with individual institutional protocols. In addition, nine patients received cyclosporin as part of their immunosuppressive therapy following ATG.
Response criteria and statistical analysis
All patients were assessed for hematological response to ATG at 6 months following treatment. The treatment response was evaluated based on defined criteria from the International Working Group on MDS. 20 Patients were evaluated for duration of response to ATG, as well as survival after administration of ATG. Overall survival (OS) was measured from day 0 to death from any cause or last known follow-up. OS was estimated using the Kaplan-Meier method and cumulative incidence curves were used to estimate time to treatment failure in patients responding to ATG with death being treated as a competing event in the analysis. Variables analyzed included age (455 vs o55 years), IPSS (low/Int-1 vs Int-2/high), BM cellularity (normo/hypercellularity vs hypocellularity), HLA-DR15 status, cytogenetics (as defined in the IPSS), blood transfusion dependence and platelet dependence. The presence of a PNH clone was not included in multivariate analysis owing to the limited number of patients tested. Cox proportional hazard regression was used to assess the significance of variables on response to ATG therapy as well as OS. Data were censored at 30 June 2006 or at time of last documented patient follow-up.
Results
The median time from diagnosis to ATG was 8.3 months (range: 0-342 months). A total of 40 patients (42%) had a hematological response as defined by Cheson et al. 20 Thirty-one patients were transfusion dependant and 18 were platelet dependent before ATG therapy. Unilineage responses were seen in 15 patients, with responses in two or more lineages in 25 patients. Thirty patients had a Hb response (24 major and six minor), 30 had a platelet response (17 major and 13 minor) and 10 patients had a response in the neutrophil lineage (eight major and two minor). Twenty-three patients were transfusion independent following therapy. Of the 40 responders, 30 patients (75%) had a durable hematological response lasting a median duration of 31.5 months at time of reporting (range: 6-92 months). Ten patients had a transient response to ATG lasting for a median of 22 months (range: 2-46 months). Of the 10 patients with a transient response to initial ATG therapy, three patients subsequently received a second course of ATG, with two patients achieving a hematological response. Two other patients had evidence of hematological improvement following further therapy with valproic acid and valproic acid with all-trans retinoic acid. Five other patients died from disease progression or infectious complications. (Characteristics of responders to ATG are detailed in Table 2 ).
At last follow-up, nine of the 40 responders had died. Four patients (with initial diagnosis of three RAEB and 1 RA-Int-1) developed and subsequently died from disease progression (three acute myeloid leukemia and one RAEB). Two patients with therapy related MDS died from relapse of their primary malignancy (one bronchial carcinoma and one Hodgkin's lymphoma). An additional three patients died of complications from cytopenia and neutropenic sepsis.
Two out of seven patients with RARS and four out of 15 patients with RAEB had an initial response to ATG. None of the patients with pre-existing chromosomal abnormalities displayed evidence of cytogenetic remission following ATG therapy. All four patients with trisomy 8 pre-therapy had no evidence of response, but three out of seven patients with isolated 5q-syndrome had a hematological response.
Of the 56 patients who failed ATG, nine patients with a median age of 48 years (range: 34-59) proceeded to receive an allogeneic reduced intensity conditioning hematopoietic stem cell transplantation (HSCT). Seven patients received a second course of ATG with three patients attaining a transient hematological response. A further four patients received a combination of growth factor support (erythropoietin or granulocyte colony-stimulating factor) together with ciclosporine. Five patients received other therapies: one thalidomide (responder), one 5-azacitidine (partial response), one lenalidomide (responder), two sodium valproate (one responder).
Factors predicting response to ATG
On univariate analysis, IPSS low/Int-1 stage and BM hypocellularity were both identified as independent factors predicting a favorable response to treatment (Table 3 ). In addition, using stepwise cox regression multivariate analysis, both variables retained significance as predictive factors for response (IPSS Int-2/high: odds ratio (OR 0.08 95% confidence interval (CI): 0.01-0.65, P ¼ 0.018 and BM normo/hypercellularity: OR 0.49 95% CI: 0.28-0.86, P ¼ 0.012). Neither HLA-DR15 status (data only available on 34 patients), age or transfusion dependence influenced responsiveness to ATG therapy.
Factors influencing OS
The overall 3-year survival of the cohort was 69.975.4%. On analysis, there was a trend for a better outcome in responders to ATG when compared with non-responders (85.276.2 vs 58.277.7%, P ¼ 0.08, see Figure 1 ). On univariate analysis, responsiveness to ATG, IPSS, cytogenetics, and transfusion dependence were all independent predictors of OS (Table 4) . However, on multivariate analysis, IPSS emerged as sole predictor of OS, with Int-2/high risk patients having a significantly poorer survival outcome (OR 6.94 95% CI: 2.85-16.95, Po0.01).
Discussion
Treatment options for low-risk MDS are limited with supportive care remaining the mainstay of therapy for the majority of patients, but it is clear that a subgroup of MDS patients can achieve a durable hematological response following immunosuppressive therapy. In our initial pilot study of 30 low-risk MDS patients within the UK, we had observed a response in 10 out of 20 evaluable patients, and other studies using ATG have reported response rates of up to 60%. 6, 7, 13, 17, 21, 22 In this study, 40 patients (42%) had evidence of hematological response, with 30 patients (31%) demonstrating a durable hematological response. On multivariate analysis, the two factors identified to predict response to ATG treatment were low/Int-1 IPSS, and BM hypocellularity.
It is clear from various studies that patients with low-risk MDS have a higher response to ATG. Of note, two patients with RARS also demonstrated a hematological response, one of which has been described previously. 7 The observation that patients with RARS may respond to ATG has since been also described by others. 14, 15 While hematological responses were observed in four patients with RAEB, three of these only had a transient response with the patients subsequently progressing to more advanced disease. When compared with the other 11 patients in the study with RAEB who did not respond to ATG, there was no significant difference in OS (P ¼ 0.47).
Broliden et al. 16 recently reported on brief cytogenetic remissions in two patients treated with ATG and cyclosporine. In addition, Sloand et al. 23 have described the increased responsiveness of patients with trisomy 8 to ATG, and correlated this with the observation that trisomy 8 cells within the BM are preferentially suppressed by cytotoxic T lymphocytes. However, none of the patients in our cohort had a cytogenetic resolution of disease, and none of the four patients with trisomy 8 (one RAEB, one RARS, two RA (Int-1)) were among the responders.
There is great heterogeneity in MDS, and patients with hypocellular MDS have been observed to share an overlap of characteristics with aplastic anemia. There is skewing of CD4:CD8 ratios, restricted T-cell receptor Vb usage together with high plasma levels of tumor necrosis factor-a and interferon-g indicating a T-cell-mediated myelosuppression. 10, 12, 24, 25 ATG has been used successfully in the alleviation of cytopenias in severe aplastic anemia, 25 and while earlier reports from Molldrem et al. and Killick et al. had identified BM hypocellularity as an important factor predicting with ATG response, several recent reports have failed to confirm this association. [14] [15] [16] 22 Our study indicates that patients with hypocellular MDS have the highest response to ATG, although responses are observed in some patients with normo/hypercellular BMs. Of note, when compared with previous studies, a higher proportion of patients (55%) in this study had a hypocellular BM, which suggests a physician bias towards the use of ATG therapy in this cohort of patients.
Saunthararajah et al. 15, 22 have previously identified the presence of HLA-DR15 as a primary factor linked with treatment responsiveness to ATG. The frequency of HLA-DR15 has been shown to be higher in both RA as well as aplastic anemia, although only patients with RA have been noted to have a higher response rate to ATG. 26, 27 While only 34 patients were tested for HLA-DR15 in this study, a high proportion (10 patients, 29%) was found to be positive for HLA-DR15, similar to the reported incidence of 30-36% among MDS patients in other studies. However, within a limited analysis of this subset of patients, HLA-DR15 positivity was not a predictive factor for ATG response (P ¼ 0.68).
In addition to ATG, other immunosuppressive and immunomodulatory agents including enternacept and ciclosporine have been used with varying success in the management of low-risk MDS. Of those only achieving a transient response or not responding to ATG, hematological response was seen in several patients to a variety of alternative immunosuppressive agents. The development of methods to assess immunological responses following ATG therapy may assist in identifying patients who may benefit from maintenance therapy, or require treatment with an alternative IST. Conversely, patients who are less likely to respond to IST should be considered for more intensive therapies where suitable. Nine non-responders (median age of 48 years) in the study eventually proceeded to allogeneic HSCT, and it should be emphasized that at present, allogeneic HSCT remains the only curative treatment for MDS. On multivariate analysis, Int2/high IPSS score is associated with a significantly lower overall survival.
In conclusion, this study confirms BM hypocellularity and a low IPSS as important factors predicting response to ATG. The findings from our study, taken together with other similar studies suggest that there are likely to be several co-dominant immunological factors contributing to the pathophysiobiology of low-risk MDS. Further studies on the immunological factors influencing the pathogenesis of low-risk MDS are necessary to identify patients who will respond best to immunosuppressive therapy, as well as establishing the most appropriate IST for each individual.
